The First Affiliated Hospital of Xiamen University, Xiamen, China.
Fujian University of Traditional Chinese Medicine, Fuzhou, China.
Front Public Health. 2022 Oct 24;10:1038017. doi: 10.3389/fpubh.2022.1038017. eCollection 2022.
COVID-19, referred to as new coronary pneumonia, is an acute infectious disease caused by a new type of coronavirus SARS-CoV-2. To evaluate the effect of integrated Chinese medicine and Western medicine in patients with COVID-19 from overseas. Data were collected from 178 COVID-19 patients overseas at First Affiliated Hospital of Xiamen University from April 1, 2021 to July 31, 2021. These patients received therapy of integrated Chinese medicine and western medicine. Demographic data and clinical characteristics were extracted and analyzed. In addition, the prescription which induced less length of PCR positive days and hospitalization days than the median value was obtained. The top 4 frequently used Chinese medicine and virus-related genes were analyzed by network pharmacology and bioinformatics analysis. According to the chest computed tomography (CT) measurement, abnormal lung findings were observed in 145 subjects. The median length of positive PCR/hospitalization days was 7/7 days for asymptomatic subjects, 14/24 days for mild subjects, 10/15 days for moderate subjects, and 14/20 days for severe subjects. The most frequently used Chinese medicine were (Huangqin), (Gancao) (Chaihu), and (Banxia). The putative active ingredients were baicalin, stigmasterol, sigmoidin-B, cubebin, and troxerutin. ACE, SARS-CoV-2 3CL, SARS-CoV-2 Spike, SARS-CoV-2 ORF7a, and caspase-6 showed good binding properties to active ingredients. In conclusion, the clinical results showed that integrated Chinese medicine and Western medicine are effective in treating COVID-19 patients from overseas. Based on the clinical outcomes, the putative ingredients from Chinese medicine and the potential targets of SARS-CoV-2 were provided, which could provide a reference for the clinical application of Chinese medicine in treating COVID-19 worldwide.
新型冠状病毒肺炎（COVID-19），简称“新冠肺炎”，是由一种新型冠状病毒 SARS-CoV-2 引起的急性传染性疾病。为评价中西医结合治疗境外输入新型冠状病毒肺炎（COVID-19）的效果，收集 2021 年 4 月 1 日至 2021 年 7 月 31 日厦门大学附属第一医院收治的 178 例境外输入 COVID-19 患者的临床资料，患者均接受中西医结合治疗，提取并分析患者的人口学资料和临床特征，得到处方中使 PCR 阳性天数和住院天数中位数减少的药物，采用网络药理学和生物信息学分析方法分析前 4 位常用中药及其与病毒相关的基因。根据胸部计算机断层扫描（CT）测量，145 例患者存在异常肺部表现。无症状患者 PCR 阳性/住院天数中位数为 7/7 天，轻症患者为 14/24 天，普通型患者为 10/15 天，重型患者为 14/20 天。最常用的中药有 （黄芩）、 （甘草）、 （柴胡）和 （半夏）。推测的活性成分有黄芩苷、豆甾醇、山柰酚-3-O-新橙皮糖苷、胡椒碱和曲克芦丁。ACE、SARS-CoV-2 3CL、SARS-CoV-2 刺突蛋白、SARS-CoV-2 ORF7a 和半胱氨酸蛋白酶-6 与活性成分具有良好的结合特性。结论：临床结果表明，中西医结合治疗境外输入 COVID-19 患者有效。基于临床疗效，推测中药的有效成分及 SARS-CoV-2 的潜在靶点，为中药治疗全球 COVID-19 提供参考。
